First patient treated with implant for regenerative repair of articular cartilage and bone

Share this story with your network

Orthomimetics, the UK based regenerative medicine company, has enrolled the first patient in its European pilot clinical trial of Chondromimetic, the company’s flagship product for the repair of articular cartilage and bone.

The single-centre study is being conducted under the supervision of world-renowned surgeon Professor Laszlo Hangody in Budapest, Hungary. The trial will evaluate the safety and efficacy of Chondromimetic using multiple outcome variables, and marks the beginning of Orthomimetics’ comprehensive evidence-based clinical program to support the launch of Chondromimetic.

Chondromimetic is a resorbable medical device that supports the body’s natural repair mechanisms to encourage the simultaneous repair of both articular cartilage and the bone to which it is attached. Chondromimetic harnesses Orthomimetics’ proprietary materials technology that produces novel mechanical properties without the need for synthetic polymers or other additives that can produce adverse degradation products.

Leave a Comment

Your email address will not be published. Required fields are marked *

*